WO2019006401A3 - Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof - Google Patents
Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof Download PDFInfo
- Publication number
- WO2019006401A3 WO2019006401A3 PCT/US2018/040457 US2018040457W WO2019006401A3 WO 2019006401 A3 WO2019006401 A3 WO 2019006401A3 US 2018040457 W US2018040457 W US 2018040457W WO 2019006401 A3 WO2019006401 A3 WO 2019006401A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- fusion polypeptides
- expressing
- nucleic acids
- subject
- Prior art date
Links
- 102100022748 Wilms tumor protein Human genes 0.000 title abstract 11
- 101710127857 Wilms tumor protein Proteins 0.000 title abstract 11
- 241000186781 Listeria Species 0.000 title abstract 6
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 10
- 206010028980 Neoplasm Diseases 0.000 abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 8
- 230000004927 fusion Effects 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 241000894006 Bacteria Species 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 4
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000607479 Yersinia pestis Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Provided herein are recombinant fusion polypeptides comprising one or more antigenic Wilms tumor protein (WT1) peptides, wherein at least one of the antigenic WT1 peptides is a heteroclitic mutant WT1 peptide (e.g., fused to a PEST-containing peptide). Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains. Also provided herein are methods of generating such fusion polypeptides, such nucleic acids, and such recombinant bacteria or Listeria strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such fusion polypeptides, such nucleic acids, or such recombinant bacteria or Listeria strains. Also provided are methods of inducing an anti-WT1 immune response in a subject, methods of inducing an anti-WT1-expressing-tumor or anti-WT1-expressing-cancer immune response in a subject, methods of treating a WT1-expressing or WT1-associated tumor or cancer in a subject, methods of preventing a WT1-expressing or WT1-associated tumor or cancer in a subject, and methods of protecting a subject against a WT1-expressing or WT1-associated tumor or cancer using such recombinant fusion polypeptides, nucleic acids, recombinant bacteria or Listeria strains, immunogenic compositions, pharmaceutical compositions, or vaccines.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527793P | 2017-06-30 | 2017-06-30 | |
| US62/527,793 | 2017-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2019006401A2 WO2019006401A2 (en) | 2019-01-03 |
| WO2019006401A3 true WO2019006401A3 (en) | 2019-04-25 |
Family
ID=64742275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2018/040457 WO2019006401A2 (en) | 2017-06-30 | 2018-06-29 | Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2019006401A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| MA41644A (en) | 2015-03-03 | 2018-01-09 | Advaxis Inc | LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF |
| NZ753307A (en) | 2016-11-30 | 2023-10-27 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| KR20200044982A (en) | 2017-09-19 | 2020-04-29 | 어드박시스, 인크. | Composition and method for lyophilization of bacteria or Listeria strains |
| CA3136352A1 (en) * | 2019-04-10 | 2020-10-15 | Slsg Limited Llc | Multi-valent immunotherapy composition and methods of use for treating wt1-positive cancers |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110223187A1 (en) * | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
| US20150352201A1 (en) * | 2013-01-15 | 2015-12-10 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| US20160228530A1 (en) * | 2014-10-14 | 2016-08-11 | The Trustees Of The University Of Pennsylvania | Combination therapy for use in cancer therapy |
| WO2016141121A1 (en) * | 2015-03-03 | 2016-09-09 | Advaxis, Inc. | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof |
| WO2016191545A1 (en) * | 2015-05-26 | 2016-12-01 | Advaxis, Inc. | Personalized delivery vector-based immunotherapy and uses thereof |
| WO2017087857A1 (en) * | 2015-11-20 | 2017-05-26 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treating cancer |
-
2018
- 2018-06-29 WO PCT/US2018/040457 patent/WO2019006401A2/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110223187A1 (en) * | 2010-02-15 | 2011-09-15 | Vafa Shahabi | Live listeria-based vaccines for central nervous system therapy |
| US20150352201A1 (en) * | 2013-01-15 | 2015-12-10 | Memorial Sloan Kettering Cancer Center | Immunogenic wt-1 peptides and methods of use thereof |
| US20160228530A1 (en) * | 2014-10-14 | 2016-08-11 | The Trustees Of The University Of Pennsylvania | Combination therapy for use in cancer therapy |
| WO2016141121A1 (en) * | 2015-03-03 | 2016-09-09 | Advaxis, Inc. | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof |
| WO2016191545A1 (en) * | 2015-05-26 | 2016-12-01 | Advaxis, Inc. | Personalized delivery vector-based immunotherapy and uses thereof |
| WO2017087857A1 (en) * | 2015-11-20 | 2017-05-26 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019006401A2 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ753307A (en) | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof | |
| WO2019006401A3 (en) | Listeria-based immunogenic compositions comprising heteroclitic wilms tumor protein antigens and methods of use thereof | |
| WO2019094607A3 (en) | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof | |
| MX2019000215A (en) | Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof. | |
| MX2017000838A (en) | Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof. | |
| AU2013370210A8 (en) | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof | |
| AU2019283892A1 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
| RU2016145464A (en) | RECOMBINANT VACCINE LISTERIA STRAINS AND METHODS FOR THEIR OBTAINING | |
| MX2018010824A (en) | Inducible binding proteins and methods of use. | |
| AR110730A1 (en) | LISTERY AND METHOD RECOMBINANT VACCINE VACCINES FOR USE IN CANCER IMMUNOTHERAPY | |
| SA518390954B1 (en) | Therapeutic HPV18 Vaccines | |
| JP2018510215A5 (en) | ||
| AR104635A1 (en) | COMPOSITIONS BASED ON IMMUNOGENIC LYSTERY THAT INCLUDE ANTIGEN AND TRUNCATED FUSIONS AND METHODS OF USE OF THESE | |
| MX2018003352A (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy. | |
| WO2017066706A8 (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| MX2020010421A (en) | T-cell inducing vaccine composition combinations and uses thereof. | |
| SG10201903349YA (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| WO2009130618A3 (en) | Flagellin polypeptide vaccines | |
| PH12019500591A1 (en) | Canine adenovirus vectors | |
| MX2022003658A (en) | Hbv vaccines and methods treating hbv. | |
| WO2019195314A3 (en) | Antigenic epstein barr virus polypeptides | |
| MX2022007902A (en) | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy. | |
| NZ601609A (en) | Vaccine vectors and methods of enhancing immune responses | |
| EA201890042A1 (en) | VACCINE AGAINST THE VIRUS OF THE DIAGRAM (VL) BASED ON A RECOMBINANT MODIFIED VIRUS OF ANPARA VOCUS ANKARA (MVA) | |
| WO2005046621A3 (en) | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18822718 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18822718 Country of ref document: EP Kind code of ref document: A2 |